These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 7972567)

  • 1. Does the change of psychopathology during the placebo period predict the response to subsequent treatment with active medication.
    Libiger J; Czobor P; Volavka J
    Psychiatry Res; 1994 May; 52(2):107-14. PubMed ID: 7972567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Haloperidol blood levels and effects in schizophrenia and schizoaffective disorder: a progress report.
    Volavka J; Cooper TB; Meisner M; Bitter I; Czobor P; Jaeger J
    Psychopharmacol Bull; 1990; 26(1):13-7. PubMed ID: 2371368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of subtle neurological dysfunction on response to haloperidol treatment in schizophrenia.
    Convit A; Volavka J; Czobor P; de Asis J; Evangelista C
    Am J Psychiatry; 1994 Jan; 151(1):49-56. PubMed ID: 8267134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder.
    Meltzer HY; Arvanitis L; Bauer D; Rein W;
    Am J Psychiatry; 2004 Jun; 161(6):975-84. PubMed ID: 15169685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Haloperidol blood levels and clinical effects.
    Volavka J; Cooper T; Czobor P; Bitter I; Meisner M; Laska E; Gastanaga P; Krakowski M; Chou JC; Crowner M
    Arch Gen Psychiatry; 1992 May; 49(5):354-61. PubMed ID: 1586270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Haloperidol response and plasma catecholamines and their metabolites.
    Green AI; Alam MY; Boshes RA; Waternaux C; Pappalardo KM; Fitzgibbon ME; Tsuang MT; Schildkraut JJ
    Schizophr Res; 1993 Jun; 10(1):33-7. PubMed ID: 8369230
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors affecting the clinical response to haloperidol therapy in schizophrenia.
    Bareggi SR; Mauri M; Cavallaro R; Regazzetti MG; Moro AR
    Clin Neuropharmacol; 1990; 13 Suppl 1():S29-34. PubMed ID: 2379182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma/RBC haloperidol ratios and improvement in acute psychotic symptoms.
    Neborsky RJ; Janowsky DS; Perel JM; Munson E; Depry D
    J Clin Psychiatry; 1984 Jan; 45(1):10-3. PubMed ID: 6363395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma haloperidol levels and clinical effects in schizophrenia and schizoaffective disorder.
    Volavka J; Cooper TB; Czobor P; Meisner M
    Arch Gen Psychiatry; 1995 Oct; 52(10):837-45. PubMed ID: 7575103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group.
    Arvanitis LA; Miller BG
    Biol Psychiatry; 1997 Aug; 42(4):233-46. PubMed ID: 9270900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.
    Citrome L; Meng X; Hochfeld M; Stahl SM
    Hum Psychopharmacol; 2012 Jan; 27(1):24-32. PubMed ID: 22161738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RBC and plasma levels of haloperidol and clinical response in schizophrenia.
    Smith RC; Vroulis G; Shvartsburd A; Allen R; Lewis N; Schoolar JC; Chojnacki M; Johnson R
    Am J Psychiatry; 1982 Aug; 139(8):1054-6. PubMed ID: 7091432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic window of serum haloperidol concentration in acute schizophrenia and schizoaffective disorder.
    Ulrich S; Neuhof S; Braun V; Meyer FP
    Pharmacopsychiatry; 1998 Sep; 31(5):163-9. PubMed ID: 9832347
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative efficacy of red cell and plasma haloperidol as predictors of clinical response in schizophrenia.
    Smith RC; Baumgartner R; Shvartsburd A; Ravichandran GK; Vroulis G; Mauldin M
    Psychopharmacology (Berl); 1985; 85(4):449-55. PubMed ID: 2862652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial.
    Tollefson GD; Beasley CM; Tran PV; Street JS; Krueger JA; Tamura RN; Graffeo KA; Thieme ME
    Am J Psychiatry; 1997 Apr; 154(4):457-65. PubMed ID: 9090331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group.
    Small JG; Hirsch SR; Arvanitis LA; Miller BG; Link CG
    Arch Gen Psychiatry; 1997 Jun; 54(6):549-57. PubMed ID: 9193196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antipsychotic efficacy of the antidepressant trimipramine: a randomized, double-blind comparison with the phenothiazine perazine.
    Bender S; Olbrich HM; Fischer W; Hornstein C; Schoene W; Falkai P; Haarmann C; Berger M; Gastpar M;
    Pharmacopsychiatry; 2003; 36(2):61-9. PubMed ID: 12734763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial.
    Shim JC; Shin JG; Kelly DL; Jung DU; Seo YS; Liu KH; Shon JH; Conley RR
    Am J Psychiatry; 2007 Sep; 164(9):1404-10. PubMed ID: 17728426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder.
    Swainston Harrison T; Perry CM
    Drugs; 2004; 64(15):1715-36. PubMed ID: 15257633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Haloperidol. Plasma levels and prolactin response as predictors of clinical improvement in schizophrenia: chemical v radioreceptor plasma level assays.
    Smith RC; Baumgartner R; Misra CH; Mauldin M; Shvartsburd A; Ho BT; DeJohn C
    Arch Gen Psychiatry; 1984 Nov; 41(11):1044-9. PubMed ID: 6497566
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.